1. Search Result
Search Result
Results for "

BTB

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

24

Recombinant Proteins

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101770

    Microtubule/Tubulin Cancer
    BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
    BTB-1
  • HY-15877
    BTB06584
    2 Publications Verification

    ATP Synthase Cancer
    BTB06584 is a selective and IF1-dependent mitochondrial F1Fo-ATPase inhibitor without compromising ATP synthesis. BTB06584 can delays ischaemic cell death .
    BTB06584
  • HY-149164
    BTB09089
    1 Publications Verification

    Others Neurological Disease Inflammation/Immunology
    BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages .
    BTB09089
  • HY-161138

    BCL6 Apoptosis Cancer
    WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
    WK369
  • HY-111381
    BI-3812
    1 Publications Verification

    Bcl-2 Family Cancer
    BI-3812 is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
    BI-3812
  • HY-160509

    TRP Channel Neurological Disease
    BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease .
    BTB 06061
  • HY-153691

    Others Others
    BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain .
    BTB01303
  • HY-P10543

    BCL6 Cancer
    SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
    SMRT peptide
  • HY-163136

    Autophagy REV-ERB Cancer
    Autophagy/REV-ERB-IN-1 (compound 24) is a dual inhibitor of autophagy and REV-ERB. Autophagy/REV-ERB-IN-1 has anti-tumor activity with a CC50 value of 2.3 μM on BTB-474 cells.
    Autophagy/REV-ERB-IN-1
  • HY-W133897

    Biochemical Assay Reagents Others
    tert-Butylamine borane is a mild reducing agent. tert-Butylamine borane involves in the selective reduction of aldehydes and ketones to the corresponding alcohols .
    tert-Butylamine borane
  • HY-108705

    Molecular Glues Bcl-2 Family Cancer
    BI-3802 is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
    BI-3802
  • HY-162152

    Keap1-Nrf2 Inflammation/Immunology
    biKEAP1 (compound 3) is an inhibitor targeting the dimerKEAP1. biKEAP1 binds to cellular KEAP1 dimers and releases the NRF2 protein sequestered by KEAP1, resulting in immediate activation of NRF2. biKEAP1 also promotes nuclear translocation of NRF2 and directly inhibits proinflammatory cytokine transcription. biKEAP1 can reduce acute inflammation and reduce inflammatory damage in acute inflammation models .
    biKEAP1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: